SCHEMBL13049702

SCHEMBL13049702

Cc1ccc(-c2oc3ccccc3c2CO)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.47
▸ KMT2A Q03164 8/20 0.47
▸ MAPT P10636 7/20 0.47
▸ CYP3A4 P08684 7/20 0.47
▸ KDM4E B2RXH2 7/20 0.47
▸ TP53 P04637 6/20 0.47
▸ HSD17B10 Q99714 6/20 0.47
▸ ALOX12 P18054 4/20 0.47
▸ MAPK1 P28482 4/20 0.47
▸ ALOX15 P16050 3/20 0.47
▸ CYP2D6 P10635 3/20 0.47
▸ CYP2C9 P11712 3/20 0.47
▸ CYP2C19 P33261 3/20 0.47
▸ ST6GAL1 P15907 2/20 0.47
▸ CDK2 P24941 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ PTPN1 P18031 2/20 0.43
▸ ACP1 P24666 2/20 0.43
▸ LMNA P02545 2/20 0.42
▸ TSHR P16473 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049689 0.89 MEN1 (0.47) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL13049757 0.82 KMT2A (0.39) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL13049701 0.81 LMNA (0.57) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL13049690 0.80 MEN1 (0.60) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL2962849 0.77 KMT2A (0.53) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL13049706 0.76 PTPN1 (0.45) MEN1KMT2ACYP3A4KDM4ETP53
SCHEMBL13049691 0.75 MEN1 (0.43) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL13080176 0.75 CYP3A4 (0.42) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL13049711 0.74 KDM4E (0.49) MEN1KMT2AMAPTCYP3A4KDM4E
SCHEMBL13049693 0.74 MAPT (0.48) MEN1KMT2AMAPTCYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
EP-1631561-B1 COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID GEN ELECTRIC (US) 2010-08-18 — — EP disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 MEN1 1513/4885KMT2A 4355/4885MAPT 170/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 MEN1 1254/4885KMT2A 4536/4885MAPT 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback